PRDM14 and breast cancer: Survival analysis on 40 tissue samples (high PRDM14 levels: n=21 samples (stage II: n=12, stage III: n = 9), low or undetectable levels: n=19 (stage II: n = 11, stage III: n = 8)) from breast cancer patients showed that PRDM14+ patients had worse prognoses than PRDM14− patients (Figure 1F).